Not available
Quote | Celsion Corporation (NASDAQ:CLSN)
Last: | $1.96 |
---|---|
Change Percent: | 0.0% |
Open: | $1.96 |
Close: | $1.96 |
High: | $1.9999 |
Low: | $1.9286 |
Volume: | 57,866 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Celsion Corporation (NASDAQ:CLSN)
Celsion ( NASDAQ: CLSN ) announced Monday its decision to change company's name to Imunon. The new name of clinical-stage drug development company is claimed to outline the "evolution of its business and its commitment to developing cutting-edge immunotherapies and next-ge...
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company, today announced ...
Message Board Posts | Celsion Corporation (NASDAQ:CLSN)
Subject | By | Source | When |
---|---|---|---|
The typical gap and trap. | traderbbc1 | investorshub | 04/08/2022 1:18:09 PM |
lol.... | TheFinalCD | investorshub | 04/07/2022 5:17:10 PM |
How's this working out for you? | traderbbc1 | investorshub | 04/07/2022 3:51:43 PM |
https://finviz.com/quote.ashx?t=$CLSN looks like OS traded today | TheFinalCD | investorshub | 04/05/2022 6:42:58 PM |
https://twitter.com/READY_2_PROFIT/status/1511399414497218566 | TheFinalCD | investorshub | 04/05/2022 6:33:35 PM |
News, Short Squeeze, Breakout and More Instantly...
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage drug development company, today announced ...
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-ba...
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24 th An...